Summary
- As the sector makes the transition from creative limitation to genuine innovation
- Harmonization was another key theme, in order to facilitate both "coming in" and "going out"
Regulatory Developments in the China Pharmaceutical and Medtech Sector in 2024, and the Outlook for 2025
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
By Ting Wu